OrthoPediatrics Corp. Expands Specialty Bracing Portfolio with DF2® Brace
26 Novembre 2024 - 10:05PM
OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq:
KIDS), a company dedicated exclusively to advancing the field of
pediatric orthopedics, is excited to announce significant updates
to the DF2® Brace, a cornerstone product within the OrthoPediatrics
Specialty Bracing business (“OPSB”). The DF2 Brace updates include
expanded indications for use, enhanced sizing options, and
additional international markets.
The DF2 Brace, which has seen strong adoption in
the U.S. as an alternative to traditional spica casting, is now
indicated for post-operative stabilization in addition to its use
for femur fracture fixation. The brace also offers extended sizing
options, including XS, S, M, L, XL, and XXL, to meet the needs of a
broader patient population.
Building on its domestic success, the DF2 Brace
has now been launched in Europe, the Middle East, and
Asia-Pacific markets. The OPSB leadership team achieved this
milestone by accelerating regulatory and hospital approvals and
leveraging robust support from key opinion leaders outside the
United States. These efforts underscore the Company’s commitment to
making the DF2 Brace accessible to pediatric orthopedic surgeons
globally.
Joe Hauser, President of OrthoPediatrics Trauma,
Deformity Correction and Specialty Bracing divisions commented,
“These updates represent the successful execution of our larger
overall strategy, and I am proud that we have expanded indications
for use, enhanced the sizing options, and launched in additional
international markets with this product. The DF2 Brace highlights
our commitment to advancing care for kids by providing an
alternative to spica casting that is a huge improvement in the
quality of life for patients and their families. With its expanded
indications and availability in new markets, we are excited about
the opportunities this innovation creates to improve outcomes for
young patients worldwide. We have a robust pipeline of development
projects, and our team will continue bringing innovative solutions
to our customers for non-operative care through the OP Specialty
Bracing division and we look forward to future milestones such as
this.”
Product Indications:The DF2
Brace is intended for femur fracture fixation and post-operative
stabilization in pediatric patients approximately 6 months to 5
years of age. It provides immobilization of the femur, knee, and
hip, offering a modern solution that enhances patient care and
recovery.
About OrthoPediatrics
Corp.Founded in 2006, OrthoPediatrics is an orthopedic
company focused exclusively on advancing the field of pediatric
orthopedics. As such it has developed the most comprehensive
product offering to the pediatric orthopedic market to improve the
lives of children with orthopedic conditions. OrthoPediatrics
currently markets over 70 products that serve three of the largest
categories within the pediatric orthopedic market. This product
offering spans trauma and deformity, scoliosis, and sports
medicine/other procedures. OrthoPediatrics’ global sales
organization is focused exclusively on pediatric orthopedics and
distributes its products in the United States and over 70 countries
outside the United States. For more information, please visit
www.orthopediatrics.com. For more information about the DF2® Brace
and OrthoPediatrics’ Specialty Bracing portfolio, please
visit https://opsb.com/.
Investor ContactPhilip Trip
TaylorGilmartin Groupphilip@gilmartinir.com415-937-5406
OrthoPediatrics (NASDAQ:KIDS)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
OrthoPediatrics (NASDAQ:KIDS)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024